National Health Act 1953 - Amendment determinations under sections 85, 85A and 88 - pharmaceutical benefits (No. PB 129 of 2009)

Overview

The National Health Act 1953, enacted by the Australian Parliament, is the legislative foundation for the Pharmaceutical Benefits Scheme (PBS), which ensures Australians have affordable and timely access to a wide range of medicines. The Act was amended to address gaps in the coverage and administration of pharmaceuticals under the PBS. The problem this Act was introduced to address was ensuring that the PBS remained effective and responsive to the changing needs of the Australian population by providing a mechanism for the Commonwealth to determine the forms, brands, and prescribing conditions of listed drugs. The Minister for Health, as the enacting authority, is empowered to make determinations under sections 85, 85A, and 88 of the Act, thereby facilitating adjustments to the PBS in line with medical and economic considerations. The Explanatory Statement for Instrument Number PB 129 of 2009 provides the context for amendments made to the PBS in accordance with recommendations from the Pharmaceutical Benefits Advisory Committee (PBAC). These amendments, which took effect on 1 February 2010, included the addition and deletion of certain drug brands and forms, as well as changes to prescribing conditions. The PBAC's role in recommending changes ensures a balanced consideration of clinical effectiveness, safety, and cost-effectiveness, which aligns with the policy objective of maintaining a sustainable and efficient PBS.

Scope and Application

The National Health Act 1953 (the Act) provides the legal foundation for the Pharmaceutical Benefits Scheme (PBS), ensuring that Australians have access to reliable, timely, and affordable medications. The Act applies to pharmaceutical benefits provided by the Commonwealth, specifically to drugs and medicinal preparations declared by the Minister to be listed drugs under subsection 85(2). These drugs and preparations are listed in legislative instruments and defined in subsection 84(1). The Act also applies to extemporaneously-prepared medicinal preparations as a result of declarations under paragraph 85(2)(b). The Minister is authorised by the Act to determine the form or forms of a listed drug by reference to strength, type of unit, size of unit, or otherwise, under subsection 85(3), and the manner of administration of a form of a listed drug under subsection 85(5). Furthermore, the Minister can determine a brand of a pharmaceutical item under subsection 85(6). The Act applies nationally, covering all Australians who access medications through the PBS. While the Act primarily focuses on ensuring access to pharmaceutical benefits, it does not explicitly outline exclusions, exemptions, or thresholds within the provided text. However, the Pharmaceutical Benefits Advisory Committee (PBAC) plays a significant role in recommending which drugs and medicinal preparations should be available as pharmaceutical benefits, taking into account factors such as clinical effectiveness, safety, and cost-effectiveness.

Key Provisions

The primary operative sections of the National Health Act 1953, as amended by the legislative instrument F2010L00101, establish the framework for the Pharmaceutical Benefits Scheme (PBS). Section 85(1) mandates that the Commonwealth provides pharmaceutical benefits in accordance with Part VII of the Act. Subsection 85(2) allows the Minister to declare, through legislative instrument, which drugs and medicinal preparations are subject to the PBS, known as listed drugs as defined in subsection 84(1). Additionally, subsections 85(3), 85(5), and 85(6) empower the Minister to determine the form, administration, and brand of listed drugs through legislative instruments. Subsection 85A(2) permits the Minister to set the conditions for prescribing pharmaceutical benefits, including the maximum quantity, number of units, and manner of administration in prescriptions. Section 88 provides for the authorisation of dental practitioners to prescribe pharmaceutical benefits. The obligations imposed by the Act on the parties and entities it governs include the declaration and management of listed drugs by the Minister. The Minister must determine the form, manner of administration, and brand of listed drugs, as well as the conditions for prescribing these drugs. This involves consultations with relevant stakeholders and expert bodies such as the Pharmaceutical Benefits Advisory Committee (PBAC). The Minister must ensure that the PBS provides reliable, timely, and affordable access to a wide range of medicines for all Australians. Furthermore, the Act mandates that the Minister consider the clinical effectiveness, safety, and cost-effectiveness of drugs when making recommendations for inclusion on the PBS. Breaches of the provisions under the National Health Act 1953 may result in both civil and criminal consequences. Although the specific penalties are not detailed in the legislative instrument, breaches of similar legislative provisions can result in significant fines and imprisonment. For example, supplying a pharmaceutical benefit that is not authorised under the PBS can be considered an offence, potentially leading to substantial penalties. The precise penalties would depend on the nature and severity of the breach, as well as any relevant case law or regulatory guidelines. It is essential for parties and entities governed by the Act to adhere strictly to the declared forms, brands, and prescribing conditions to avoid any legal repercussions.